摘要
抗体偶联药物(ADC)是通过特定化学连接子将单克隆抗体和细胞毒药物锚定而成的免疫偶联物,在减少毒副作用的同时保留了抗体的高特异性和细胞毒素对肿瘤的高毒性,是未来肿瘤药物治疗领域的研究热点。最近,美国食品和药物管理局已经批准靶向连接蛋白4的ADC enfortumab vedotin用于局部晚期或转移性尿路上皮癌治疗,不少针对泌尿系肿瘤的ADC基础及临床研究正在进行中。
Antibody drug conjugate(ADC) is an immunoconjugate formed by anchoring monoclonal antibodies and cytotoxic drugs through specific chemical linkers. It reduces the toxicity and side effects of drugs while retaining the high specificity of antibodies and the high toxicity of cytotoxic drugs, which is a research hotspot in the field of cancer drug therapy in the future. Recently, the U.S. Food and Drug Administration has approved enfortumab vedotin which targeted nectin-4 for the treatment of locally advanced or metastatic urothelial carcinoma. Many ADCs targeting urologic neoplasms are undergoing basic research and clinical trials at different stages.
作者
潘锦锋
马琪
PAN Jin-feng;MA Qi(Schoo of Medicine,Ningbo University,Ningbo ZHEJIANG 315211,China;Translational Research Key laboratory for Urology Disease,Ningbo First Hopial,Ningbo ZHEJIANG 315010,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2020年第12期705-710,共6页
Chinese Journal of New Drugs and Clinical Remedies
基金
浙江省自然科学基金(LY20H050002)
宁波市自然科学基金(2018A610297)
浙江省医药卫生科技计划项目(2016KYB263)。
关键词
泌尿系肿瘤
免疫轭合物
治疗结果
抗体偶联药物
urologic neoplasms
immunoconjugates
treatment outcome
antibody drug conjugate
